TY - JOUR T1 - Time on therapy and concomitant medication use of mepolizumab in Canada: A retrospective cohort study JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00778-2020 SP - 00778-2020 AU - J.K. Lee AU - A. Gendron AU - M. Knutson AU - N. Sriskandarajah AU - L. Mbuagbaw AU - S.G. Noorduyn Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/02/04/23120541.00778-2020.abstract N2 - Asthma is a chronic inflammatory condition that affects 3.8 million Canadians and nearly 65,000 acute asthma exacerbations occur each year [1–4]. Left untreated, asthma can lead to increasing mortality and morbidity [2, 5, 6]. Economically, the projected 20-year total costs (2014–2033) of sub-optimal asthma control in Canada are estimated to be $213 billion, of which the majority ($195 Billion) were productivity losses (presenteeism & absenteeism) [7].FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of Interest: SG Noorduyn reports employment with AstraZeneca Canada both during the conduct of the study and outside the submitted work. ER -